Rapp stock hits all-time high at 44.28 USD
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rapport Therapeutics Inc (RAPP)
Rapport Therapeutics Inc stock price live, this page displays NASDAQ RAPP stock exchange data. View the RAPP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rapport Therapeutics Inc real time stock price chart below.
What Is the Rapport Therapeutics Inc Stock Price Today?
The Rapport Therapeutics Inc stock price today is 40.94.
What Is the Stock Symbol for Rapport Therapeutics Inc?
The stock symbol for Rapport Therapeutics Inc is "RAPP."
What Stock Exchange Does Rapport Therapeutics Inc Trade On?
Rapport Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Rapport Therapeutics Inc a Good Stock to Buy?
Determining whether Rapport Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RAPP quote. (ISIN: US75383L1026)
What Is the Rapport Therapeutics Inc Stock Price Today?
The Rapport Therapeutics Inc stock price today is 40.94.
What Is the Stock Symbol for Rapport Therapeutics Inc?
The stock symbol for Rapport Therapeutics Inc is "RAPP."
What Stock Exchange Does Rapport Therapeutics Inc Trade On?
Rapport Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Rapport Therapeutics Inc a Good Stock to Buy?
Determining whether Rapport Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RAPP quote. (ISIN: US75383L1026)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.73
42.66
52 wk Range
13.62
44.28
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.7342.66
52 wk Range
13.6244.28
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RAPP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
58.59
Upside
+43.10%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
- Rapp stock hits all-time high at 44.28 USD
- Investing.com
Form 4 Rapport Therapeutics Inc For: 15 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 58.59
(+43.10% Upside)
Earnings
Latest Release
May 07, 2026
EPS / Forecast
-0.42 / --
Revenue / Forecast
20M / --
Compare RAPP to Peers and Sector
Metrics to compare | RAPP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRAPPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.3x | −14.7x | −0.3x | |
PEG Ratio | −2.70 | −0.23 | 0.00 | |
Price/Book | 4.2x | 6.9x | 2.6x | |
Price / LTM Sales | 97.9x | 16.0x | 2.9x | |
Upside (Analyst Target) | 36.8% | 41.9% | 56.7% | |
Fair Value Upside | Unlock | −15.7% | 10.2% | Unlock |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Rapport Therapeutics (RAPP) Stock Price Today?
The Rapport Therapeutics stock price today is 40.94 USD.
What Stock Exchange Does Rapport Therapeutics Trade On?
Rapport Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rapport Therapeutics?
The stock symbol for Rapport Therapeutics is "RAPP."
What Is the Rapport Therapeutics Market Cap?
As of today, Rapport Therapeutics market cap is 1.96B USD.
What Is Rapport Therapeutics's Earnings Per Share (TTM)?
The Rapport Therapeutics EPS (TTM) is -2.56.
When Is the Next Rapport Therapeutics Earnings Date?
Rapport Therapeutics will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is RAPP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Rapport Therapeutics Stock Split?
Rapport Therapeutics has split 0 times.
How Many Employees Does Rapport Therapeutics Have?
Rapport Therapeutics has 84 employees.
What is the current trading status of Rapport Therapeutics (RAPP)?
As of Jul 30, 2026, Rapport Therapeutics (RAPP) is trading at a price of 40.94 USD, with a previous close of 40.94 USD. The stock has fluctuated within a day range of 40.73 USD to 42.66 USD, while its 52-week range spans from 13.62 USD to 44.28 USD.
What Is Rapport Therapeutics (RAPP) Price Target According to Analysts?
The average 12-month price target for Rapport Therapeutics is 58.59 USD, with a high estimate of 80 USD and a low estimate of 40 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.10% Upside potential.
What Is the RAPP After Hours Price?
RAPP's last after hours stock price is 41.30 USD, the stock has decreased by 0.36, or 0.88%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.